Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition
about
Pro-tumorigenic effects of miR-31 loss in mesothelioma.Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibitRegulation of AMP-activated protein kinase by natural and synthetic activatorsAMP-activated protein kinase: a target for drugs both ancient and modernAMPK: opposing the metabolic changes in both tumour cells and inflammatory cells?Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cellsA Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer.Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules.2-Deoxy-D-glucose treatment of endothelial cells induces autophagy by reactive oxygen species-mediated activation of the AMP-activated protein kinase.Pemetrexed in advanced non-small-cell lung cancer.Generalized portrait of cancer metabolic pathways inferred from a list of genes overexpressed in cancerTherapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporterAugmentation of reduced folate carrier-mediated folate/antifolate transport through an antiport mechanism with 5-aminoimidazole-4-carboxamide riboside monophosphateThe human proton-coupled folate transporter: Biology and therapeutic applications to cancer.Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors.Targeting tumour proliferation with a small-molecule inhibitor of AICAR transformylase homodimerizationAMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemiaPemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.Procarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathwaySorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cellsThe impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival.Molecular Pathways: Is AMPK a Friend or a Foe in Cancer?Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.Differential regulation of autophagy and cell viability by ceramide species.AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human TumorsNovel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates.Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signalingA marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate.The antifolatesThe membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitorTumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide BiosyParameters for individualizing systemic therapy in non-small cell lung cancerPhase I study of pemetrexed with sorafenib in advanced solid tumors.Structural and Enzymatic Analysis of Tumor-Targeted Antifolates That Inhibit Glycinamide Ribonucleotide Formyltransferase.
P2860
Q24607181-8BDCA341-5163-4727-813E-4AC1DDE6B8AEQ24631090-82319EE0-7AB1-4DD1-B34F-1FA519D89BEDQ26767334-FF3FFF0D-47CF-44D2-A300-B1D52A59B4A5Q26864424-5D718883-7B49-46AA-8424-838EDF96724EQ26866512-A3CFCFD7-E509-4D3F-A5F7-ED9A760E25F9Q28487936-50CF4234-5FCA-4D7F-A965-3FE234D4DC19Q33429306-A09707B7-00FE-47FE-A2C0-3EB44708C368Q33572258-8A70F8D6-5CAC-4E05-81F6-FEA7DC3885D1Q33658554-41D3FB54-FF56-4654-B2BB-5D161B6A840EQ33754141-433024C7-ADF8-467D-B8B6-BCB6F2BCEA3EQ33840827-3024315F-BA5F-4AB2-8135-355C1EFE4DF8Q34113895-D3B56000-89B2-4421-8993-75C0E46F7B87Q34176623-4649505E-29C0-42D0-ACFA-DAF0E70E2A83Q34218576-72401380-9808-4983-94FF-CA7C508215B1Q34272508-63E7B44E-8C40-4895-A8E5-9304BD66FD09Q34297931-D573279F-3289-4589-B174-C564E86A6E9DQ34310128-C7D3D78C-4FC2-44AD-8CEE-24D2E0606BECQ34327238-141F68B5-4B18-4A8C-A2A0-4227DAFD26AFQ34647789-80AF86BA-3B47-475A-AED7-FF77AC106142Q34686810-0BF469EB-3452-4513-90C3-9337E3FA7CC0Q34984571-CD7EF708-3EF7-4C67-A76C-ECF6E4118F04Q35113327-CA922423-55C7-4D54-AE63-3CC92A2F9CABQ35545752-57B4EEBF-0DB3-47DF-BBC8-51F7C98D2D69Q35747280-ED22617F-F795-460F-8E15-F81E229EF2A1Q36023587-EE6A7387-E1BF-474A-A807-58F5C18B06D8Q36209145-6F0757CB-561C-4718-AE1E-3B5DFF776241Q36214943-79891058-C663-46D6-86C0-354D504EB365Q36282831-234AE952-FFB0-4078-A3DC-A1676C2335BEQ36467564-9AE5AC92-7060-489B-91D7-1629CD2D9E85Q36467569-CF4D3F9A-02EF-4113-8F32-DAB15209477CQ36733474-15548F41-D0F5-488C-90E7-2B3FF27931AAQ36766720-83B5E1D5-8B71-4E84-8803-F264C1569F1BQ36919811-46343EF0-C4CF-4FF2-9DE1-1C207FAC2DE9Q37170305-81EFC261-D79F-48AB-8F50-09122E8D1805Q37183495-3598B8F7-B8BF-4009-9776-62436E4857E7Q37200566-31197DBC-0692-43D3-B563-76DE6B004D62Q37246257-99189259-D2F5-471B-82B9-1CEC003C0E56Q37398845-424F1887-9D58-476E-9A75-B213A127D9A2Q37520649-0A6451DA-5505-40B7-A948-E0197DDB36DDQ37587969-3E17836B-3A3C-42CD-BC8B-78A5C9C5221B
P2860
Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutics by cytotoxic meta ...... target of rapamycin inhibition
@en
Therapeutics by cytotoxic meta ...... arget of rapamycin inhibition.
@nl
type
label
Therapeutics by cytotoxic meta ...... target of rapamycin inhibition
@en
Therapeutics by cytotoxic meta ...... arget of rapamycin inhibition.
@nl
prefLabel
Therapeutics by cytotoxic meta ...... target of rapamycin inhibition
@en
Therapeutics by cytotoxic meta ...... arget of rapamycin inhibition.
@nl
P2093
P2860
P1433
P1476
Therapeutics by cytotoxic meta ...... target of rapamycin inhibition
@en
P2093
Alexandra C Racanelli
Cortney L Heyer
Richard G Moran
P2860
P304
P356
10.1158/0008-5472.CAN-08-4979
P407
P577
2009-06-23T00:00:00Z